NeuShen Therapeutics

We are a global biotech company dedicated to pioneering novel therapies for psychiatric and neurological disorders that impact millions of people worldwide.

NeuShen Therapeutics

We are a global biotech company dedicated to pioneering novel therapies for psychiatric and neurological disorders that impact millions of people worldwide.

Our Mission

Our Mission

At NeuShen, central nervous system (CNS) disorders are our exclusive focus. Our mission is to create innovative drug candidates that stand out. Through rigorous R&D and extensive clinical expertise, we strive daily to bring impactful medicines closer to patients.

We are a passionate group of scientists and professionals committed to advancing CNS disorder treatments. We aim to cultivate an environment where we champion the values of excellence, integrity, and collaboration.

2022

year of establishment

10 +

novel compounds in development

20 +

average years of CNS experience of our founders

20 +

proprietary IPs

Our Focus

Depression

Depression, or major depressive disorder, stands as one of the most prevalent mental health conditions worldwide, impacting every facet of a patient's life and imposing significant societal burdens. Despite the existence of various effective antidepressant drugs, the quest for improved treatments remains ongoing. We are making steady progress in this pursuit.

Read More
Depression
Schizophrenia

Schizophrenia

Schizophrenia is a severe mental disorder characterized by recurring episodes of psychosis that require long-term care. Millions of people globally are estimated to be living with this condition, for which there is currently no cure. We are actively developing novel treatments for schizophrenia that are safer and more effective.

Read More

Neurological Disorders

Neurological disorders comprise a wide range of conditions caused by abnormities in the nervous system that result in diverse symptoms affecting mobility, cognition and other functions. Prominent examples include epilepsy, Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), etc. We recognize immense opportunities in this disease area and aspire to be at the forefront of advancing innovative treatments.

Read More
Neurological Disorders

Current Pipeline

COMPOUND (TARGET)

INDICATION(S)

DISCOVERY

IND ENABLING

PHASE I

PHASE II

PHASE III

NS-041
(KCNQ2/3 activator)

Focal onset seizure

Major depressive disorder

Pain

NS-136
(mAChR4 PAM)

Schizophrenia

Psychosis in Alzheimer's disease

NS-015
(Neuroplasticity)

NS-031
(NMDAR)

NS-050
(Neuroinflammation)

Treatment-resistant depression

Treatment-resistant depression

Alzheimer's disease
Parkinson’s disease

Latest News